Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
Comparison of diclofenac with apigenin-glycosides rich Clinacanthus nutans extract for amending inflammation and catabolic protease regulations in osteoporotic-osteoarthritis rat model.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- معلومة اضافية
- المصدر:
Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101125969 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2008-2231 (Electronic) Linking ISSN: 15608115 NLM ISO Abbreviation: Daru Subsets: MEDLINE
- بيانات النشر:
Publication: 2018- : Cham : Springer International Publishing
Original Publication: Tehran, Iran : The Faculty
- الموضوع:
- نبذة مختصرة :
Background: Osteoporotic-osteoarthritis is an incapacitating musculoskeletal illness of the aged.
Objectives: The anti-inflammatory and anti-catabolic actions of Diclofenac were compared with apigenin-C-glycosides rich Clinacanthus nutans (CN) leaf extract in osteoporotic-osteoarthritis rats.
Methods: Female Sprague Dawley rats were randomized into five groups (n = 6). Four groups were bilateral ovariectomised for osteoporosis development, and osteoarthritis were induced by intra-articular injection of monosodium iodoacetate (MIA) into the right knee joints. The Sham group was sham-operated, received saline injection and deionized drinking water. The treatment groups were orally given 200 or 400 mg extract/kg body weight or 5 mg diclofenac /kg body weight daily for 28 days. Articular cartilage and bone changes were monitored by gross and histological structures, micro-CT analysis, serum protein biomarkers, and mRNA expressions for inflammation and catabolic protease genes.
Results: HPLC analysis confirmed that apigenin-C-glycosides (shaftoside, vitexin, and isovitexin) were the major compounds in the extract. The extract significantly and dose-dependently reduced cartilage erosion, bone loss, cartilage catabolic changes, serum osteoporotic-osteoarthritis biomarkers (procollagen-type-II-N-terminal-propeptide PIINP; procollagen-type-I-N-terminal-propeptide PINP; osteocalcin), inflammation (IL-1β) and mRNA expressions for nuclear-factor-kappa-beta NF-κβ, interleukin-1-beta IL-1β, cyclooxygenase-2; and matrix-metalloproteinase-13 MMP13 activities, in osteoporotic-osteoarthritis rats comparable to Diclofenac.
Conclusion: This study demonstrates that apigenin-C-glycosides at 400 mg CN extract/kg (about 0.2 mg apigenin-equivalent/kg) is comparable to diclofenac in suppressing inflammation and catabolic proteases for osteoporotic-osteoarthritis prevention. Graphical abstract.
- References:
Drug Chem Toxicol. 2016 Oct;39(4):461-73. (PMID: 27033971)
Clinics (Sao Paulo). 2013 Jun;68(6):865-75. (PMID: 23778480)
Acta Ortop Bras. 2015 Jan-Feb;23(1):34-7. (PMID: 26327793)
J Pharmacol Sci. 2019 Jan;139(1):15-22. (PMID: 30528467)
Immunol Rev. 2005 Dec;208:207-27. (PMID: 16313351)
ScientificWorldJournal. 2014;2014:724267. (PMID: 25405231)
Nat Med. 2009 Jun;15(6):682-9. (PMID: 19448637)
Connect Tissue Res. 2016 Jul;57(4):245-61. (PMID: 27285430)
Nat Rev Rheumatol. 2016 Jul;12(7):412-20. (PMID: 27192932)
Eur Cell Mater. 2011 Feb 24;21:202-20. (PMID: 21351054)
Int J Biochem Cell Biol. 2013 Nov;45(11):2580-4. (PMID: 24004831)
Nat Rev Rheumatol. 2011 Jan;7(1):33-42. (PMID: 21119608)
J Rheumatol. 2011 Aug;38(8):1680-8. (PMID: 21572148)
Scand J Immunol. 2019 Aug;90(2):e12773. (PMID: 31055848)
Physiol Genomics. 2011 Jan 7;43(1):32-42. (PMID: 20923861)
Osteoporos Int. 2014 Sep;25(9):2159-71. (PMID: 24599274)
Pharm Biol. 2017 Dec;55(1):1093-1113. (PMID: 28198202)
J Clin Diagn Res. 2015 Aug;9(8):RC04-7. (PMID: 26436008)
Osteoarthritis Cartilage. 2007 Oct;15(10):1190-8. (PMID: 17500014)
Osteoarthritis Cartilage. 2006 Jan;14(1):13-29. (PMID: 16242352)
Curr Rheumatol Rep. 2013 Nov;15(11):375. (PMID: 24072604)
Osteoarthritis Cartilage. 2014 Sep;22(9):1251-8. (PMID: 25042553)
Evid Based Complement Alternat Med. 2016;2016:1494981. (PMID: 27190528)
J Nat Prod. 2013 Jun 28;76(6):1141-9. (PMID: 23742617)
RMD Open. 2015 Aug 15;1(Suppl 1):e000061. (PMID: 26557379)
Evid Based Complement Alternat Med. 2018 Jul 4;2018:9276260. (PMID: 30105077)
Nat Rev Rheumatol. 2012 Nov;8(11):665-73. (PMID: 22868925)
Curr Opin Rheumatol. 2013 Jul;25(4):524-31. (PMID: 23680778)
Evid Based Complement Alternat Med. 2014;2014:628473. (PMID: 24511320)
Cytotechnology. 2015 Mar;67(2):357-65. (PMID: 24500394)
J Bone Joint Surg Am. 1971 Apr;53(3):523-37. (PMID: 5580011)
BMC Complement Altern Med. 2016 Jun 14;16:180. (PMID: 27301877)
Nat Rev Rheumatol. 2015 Aug;11(8):462-74. (PMID: 25900210)
Curr Osteoporos Rep. 2009 Dec;7(4):134-9. (PMID: 19968917)
Food Funct. 2018 Nov 14;9(11):5740-5749. (PMID: 30321247)
Lancet. 2013 Aug 31;382(9894):769-79. (PMID: 23726390)
BMC Musculoskelet Disord. 2012 Aug 22;13:153. (PMID: 22917179)
J Immunol. 2006 Sep 15;177(6):3799-805. (PMID: 16951341)
Biomol Ther (Seoul). 2016 Mar 1;24(2):163-70. (PMID: 26902085)
Ann Rheum Dis. 2013 Nov;72(11):1756-63. (PMID: 23897772)
Curr Drug Targets. 2010 May;11(5):599-613. (PMID: 20199390)
BMC Complement Altern Med. 2014 Jul 04;14:220. (PMID: 24993916)
Nat Med. 2004 Jun;10(6):617-24. (PMID: 15156202)
- Grant Information:
NH1014D052 Kementerian Pertanian dan Industri Asas Tani Malaysia
- Contributed Indexing:
Keywords: Anti-inflammatory; Apigenin-C-glycosides; Osteoarthritis; Osteoporosis
- الرقم المعرف:
0 (Cytokines)
0 (Glycosides)
0 (Plant Extracts)
144O8QL0L1 (Diclofenac)
7V515PI7F6 (Apigenin)
EC 3.4.24.- (Matrix Metalloproteinase 13)
EC 3.4.24.- (Mmp13 protein, rat)
WF5188V710 (Iodoacetic Acid)
- الموضوع:
Date Created: 20200511 Date Completed: 20210827 Latest Revision: 20231104
- الموضوع:
20231104
- الرقم المعرف:
PMC7704886
- الرقم المعرف:
10.1007/s40199-020-00343-y
- الرقم المعرف:
32388789
No Comments.